LNCaP: ARW741L cell line

Please Enter Your Email ID
Email ID

Cat. #154165

LNCaP: ARW741L cell line

Cat. #: 154165

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Disease: Cancer

Model: Tumour line


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Institute: Northern Institute For Cancer Research, Newcastle University

Tool Details
Target Details

Tool Details


  • Name: LNCaP: ARW741L cell line
  • Alternate name: AR, Dihydrotestosterone Receptor, Nuclear Receptor Subfamily 3 Group C Member 4, NR3C4, DHTR
  • Cancer: Genitourinary cancer
  • Cancers detailed: Human prostate adenocarcinoma
  • Research fields: Cancer
  • Tool sub type: Continuous
  • Parental cell: LNCaP
  • Organism: Human
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: No
  • Description: LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist. This cell line is the most commonly used for prostate cancer research. In approximately 30% CRPC, AR mutations are detected and are likely selected for under pressure by hormonal therapies.Mutations within the AR ligand-binding domain, the site of testosterone and anti-androgen binding, enable retention of AR signalling in the presence of hormonal therapies. Two AR LBD mutations are commonly detected in patients treated with bicalutamide and enzalutamide, W741L and F876L,respectively. These convert the activity of anti-androgens from antagonists to agonists and enable progression of CRPC. Modelling these mutations previously has been difficult and have been limited to, principally, luciferase-based assays in non-AR-expressing cell lines. We have therefore developed two key LNCaP cell derivatives that have stable expression of ARW741L and ARF876L (Cat No:154163) mutations which enables us to assess the activity of these aberrantly functioning receptors in a physiological background. Moreover, by depleting endogenous AR in LNCaP cells, we can provide a clean read-out for mutant AR activity that can be utilised for assessing efficacy of novel AR-targeting agents
  • Production details: HEK 293T cells were transfected with pLenti-FLAG-ARF876L to generate viral particles. Using a multiplicity of infection of 0.3 and 0.1, LNCaP cells were transduced with virus. Stable expressing clones were selected with 10Â?„?žg/ml blasticidin. Ectopic AR expression was determined by western blot
  • Biosafety level: 1

Target Details

  • Target: Androgen Receptor


  • Format: Frozen
  • Growth medium: RPMI-1640 + 10% FBS
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes


  • O'Neill et al. 2015. Oncotarget. 6(28):26029-40. PMID: 26267320.
  • Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.